ERK-IN-1 |
| رقم الكتالوجGC33206 |
ERK-IN-1 (المركب B) هو مثبط ERK1 و ERK2 متاح عن طريق الفم في علاج مرض تكاثر يتميز بتنشيط الطفرات في مسار MAPK. يرتبط النشاط بشكل خاص بعلاج KRAS-mutant NSCLC ، و BRAF-mutant NSCLC ، وسرطان البنكرياس المتحولة KRAS ، وسرطان القولون والمستقيم المتحولة KRAS (CRC) وسرطان المبيض المتحور KRAS. يمكن أن يمنع هيدروكلوريد ERK-IN-1 أيضًا RAF.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1715025-32-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ERK-IN-1 (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].
ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1].|| Animal Model:|Calu-6 NSCLC xenograft tumor models in mice[1].|Dosage:|50, 75 mg/kg.|Administration:|Orally either daily (qd) or every other day (q2d) for 27 days.|Result:|Significantly reduced the tumor volume.
[1]. WO2018051306A1.
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *